ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1232

The Perceived Impact of Recent-Onset Psoriatic Arthritis Is Different between Genders: A Spanish Multicenter Experience

Rubén Queiro1, Ana Laiz2, Carlos Alberto Montilla-Morales3, Eva Galindez-Agirregoikoa4, Juan J. Bethencourt5 and Daniel Seoane6, 1Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, 2Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, 3Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 4Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, 5Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, 6Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, PRO, psoriatic arthritis and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Patient Outcomes, Preferences, and Attitudes Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Some studies point to a differential clinical expression between men and women with PsA, but the information on gender differences is very scarce in the earliest stages of the disease. We aimed to describe the baseline characteristics and impact of disease among men and women included in the REAPSER (Recent-Onset PsA Registry of the Spanish Society of Rheumatology) cohort.

.

Methods:

REAPSER is an observational, multicenter study, with consecutive recruitment, that included adults of both sexes aged 18 yr or older that met CASPAR criteria for PsA, and had duration of less than two years since the appearance of symptoms attributed to PsA (recent-onset PsA). Annual follow-up visits will be carried out for 5 years. Measurements include socio-demographic data, employment status and impact of the disease, family history of PsA and other inflammatory diseases, comorbidities, lifestyle, use of health services, clinical status at disease presentation, anthropometric data, clinical evaluation of PsA manifestations, radiographic progression, analytical determinations, and treatment of the disease. The study has been approved by the ethical committees of the participating centers.

We have analyzed these aspects among men and women, with special emphasis on the perceived impact of the disease between both sexes. Descriptive statistic included central measures with dispersion values. Qualitative variables were compared by Chi-square and Fisher´s exact test. The normal quantitative variables were compared by a Student’s T test and the non-normal quantitative ones by non-parametric tests.

Results:

Parameter

Men. N: 142

Women. N: 68

p-values

Age (years)

University studies

Active worker

BMI

Waist-hip index

Smoker

Alcohol consumption

Psoriasis family history

PsA family history

Charlson´s CI (> 3)

Depression

Common Psoriasis

Pustular Psoriasis

No psoriasis

Onicopathy

PASI

Peripheral pattern

Axial pattern

Mixed Pattern

TJC68

SJC66

BASDAI (0-10)

BASFI (0-10)

Dactylitis

ESR (mm/h)

50.2 (13.8)

18.3%

65%

27.3 (4.8)

0.94 (0.1)

29.6%

45.1%

40.1%

8.5%

18.3%

7.7%

81%

2.1%

8.5%

59%

1.5 (0.6-4.4)

80.3%

7%

12.7%

4 (2-7.2)

2 (1-4)

4.1 (2.2-6)

1.8 (0.4-4.5)

31.4%

12 (5-20)

49.6 (14.1)

16.2%

49.3%

28.5 (6)

0.87 (0.1)

32.4%

16.2%

45.6%

10.3%

17.6%

19.4%

61.8%

11.8%

19.1%

49%

1.2 (0.6-3)

83.8%

1.5%

14.7%

4 (2-8)

2 (0-5)

4.8 (2.4-7.3)

2.9 (1.4-4.7)

47.1%

21 (10-29.5)

NS

NS

<0.001

NS

<0.001

NS

<0.001

NS

NS

NS

0.014

0.003

0.006

0.027

NS

NS

NS

NS

NS

NS

NS

0.008

0.065

0.028

0.001

CI: comorbidity index. PASI: Psoriasis Area and Severity Index. Data are expressed in percentages, mean with SD (Standard Deviation), median and IQR (Interquartile Range)

PROs

Men

N: 142

Women

N: 68

p-values

Pain VAS

Pat. global disease activity

PsAID

HAQ

4 (2-7)

5 (3-7)

3.1 (1.5-6.1)

0.4 (0-1)

6 (4-7)

6 (3-8)

4.2 (2.3-6)

0.8 (0.4-1)

0.025

0.042

0.063

0.010

Values are expressed as median (IQR). PROs: Patient Reported Outcomes. Pat: patient. PsAID: Psoriatic Arthritis Impact of Disease. HAQ: Health Assessment Questionnaire.

Conclusion:

Female scored higher in several PROs compared to male. Thus the perception of having a severe disease is higher in female. This information could be of help for improving medical care for women with PsA.


Disclosure: R. Queiro, None; A. Laiz, None; C. A. Montilla-Morales, None; E. Galindez-Agirregoikoa, None; J. J. Bethencourt, None; D. Seoane, None.

To cite this abstract in AMA style:

Queiro R, Laiz A, Montilla-Morales CA, Galindez-Agirregoikoa E, Bethencourt JJ, Seoane D. The Perceived Impact of Recent-Onset Psoriatic Arthritis Is Different between Genders: A Spanish Multicenter Experience [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-perceived-impact-of-recent-onset-psoriatic-arthritis-is-different-between-genders-a-spanish-multicenter-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-perceived-impact-of-recent-onset-psoriatic-arthritis-is-different-between-genders-a-spanish-multicenter-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology